Sluggish administrative procedures for approving new drugs are claimed to be responsible for unnecessary deaths. In Belgium, the lengthy and complicated registration procedure for new drugs meant an average delay of 1,000 days before the drug was on the market. In the case of a new drug for ovarian cancer, it was estimated that 120 untreated women would die during the registration period.